Education
About Us
Working with TipRanks
Follow Us
Shionogi & Co Ltd (SGIOF)
OTHER OTC:SGIOF
Top Page
Positive Factors
Acquisition
One of the key benefits of JT Pharma acquisition is to gain additional small molecule-based drug discovery research capability and capacity.
Antibiotic Sales
Our antibiotic, Fetroja, has been growing strongly in the US, +38% YoY.
HIV Royalty
HIV royalty grew strongly partly thanks to foreign exchange effects.
Negative Factors
Analyst Rating
Analyst rates Shionogi Underperform with significant downside potential.
Financial Performance
Shionogi's FY24 top and bottom lines were a slight miss versus consensus and its guidance.
Revenue Goals
There is no organic way to fill the gap for their FY25 revenue target.
Shionogi & Co (SGIOF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.80B
Dividend Yield2.67%
Average Volume (3M)0.00
Price to Earnings (P/E)11.6
Beta (1Y)0.17
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees4,955
SectorHealthcare
Sector Strength41
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.30
Shares Outstanding889,632,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.17
Price to Book (P/B)1.40
Price to Sales (P/S)0.00
P/FCF Ratio9.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16.45Price Target Upside8.22% Upside
Rating ConsensusHold
Number of Analyst Covering4
Shionogi & Co Business Overview & Revenue Model
Company DescriptionShionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
How the Company Makes Money
Shionogi & Co Earnings Call Summary
Earnings Call Date:May 12, 2025
(Q3-2024)
| % Change Since: 0.00%|
Next Earnings Date:Jul 28, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strong growth in the HIV and overseas business segments, with significant advancements in product launches and expansion. However, this was tempered by declines in overall sales revenue, increased costs, and the dissolution of a key joint venture in China.Q3-2024 Updates
Positive Updates
Strong Growth in HIV Business
The HIV franchise grew significantly, with royalty income increasing by JPY12.3 billion compared to the third quarter of last year. The LA formulation treatment increased by 43.4% year-on-year.
Overseas Business Expansion
Cefiderocol sales increased by 39.6% in the United States and 25.6% in Europe year-on-year. The number of countries where it is sold increased to 25.
Stable Domestic Infectious Disease Business
Sales of influenza and COVID-19 treatment drugs like Xofluza expanded in Q3 due to the spread of influenza in December.
Launch of New Products
The insomnia treatment drug, QUVIVIQ, was launched on December 19, marking a new sales record.
Negative Updates
Decline in Total Sales Revenue
Sales revenue was JPY333.6 billion, down JPY3.2 billion from last year's JPY336.8 billion, mainly affected by a one-time payment recorded last year.
Increased Costs and Expenses
The cost of goods increased by 8.6% year-on-year, and research and development expenses increased by 9.4% year-on-year.
Dissolution of Joint Venture in China
The joint venture with Ping An in China was dissolved due to changes in the business environment and strategy review.
Company Guidance
In the third quarter of fiscal year 2024, Shionogi & Co., Ltd. reported a sales revenue of JPY333.6 billion, a slight decrease of JPY3.2 billion year-on-year, primarily due to a one-time payment of JPY25 billion recorded in the previous year. However, excluding this payment, revenue increased by JPY21.8 billion, driven by a significant growth in royalty income and overseas business, notably the HIV franchise, which grew by JPY12.3 billion. Operating profit also saw an increase of JPY15.5 billion when excluding the one-time payment. Profit before tax reached JPY155.9 billion, with profit attributable to owners of the parent at JPY133.8 billion, marking an increase of JPY6.6 billion year-on-year. The company highlighted the stabilization of its domestic infectious disease business and expressed optimism in achieving the full-year forecast, bolstered by the success of its COVID-19 and influenza treatments, Xofluza and Xocova, as well as the launch of new products like QUVIVIQ. The yen's depreciation contributed to exchange gains, further supporting financial outcomes. Additionally, Shionogi emphasized its commitment to cost management and strategic R&D investments to sustain growth across its business segments.Shionogi & Co Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 431.86B | 435.08B | 426.68B | 335.14B | 297.18B | 333.37B | Gross Profit |
| 368.45B | 369.09B | 364.44B | 279.72B | 244.65B | 276.59B | EBIT |
| 153.96B | 171.46B | 149.00B | 110.31B | 117.44B | 130.63B | EBITDA |
| 191.79B | 217.81B | 176.41B | 143.42B | 158.67B | 174.47B | Net Income Common Stockholders |
| 168.61B | 162.03B | 184.97B | 114.19B | 111.86B | 122.19B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 305.58B | 358.09B | 563.36B | 465.18B | 418.32B | 380.02B | Total Assets |
| 1.52T | 1.42T | 1.31T | 1.15T | 998.99B | 871.53B | Total Debt |
| 23.06B | 11.62B | 9.41B | 6.67B | 7.99B | 8.15B | Net Debt |
| -282.52B | -346.47B | -299.81B | -247.75B | -268.19B | -200.71B | Total Liabilities |
| 153.98B | 164.36B | 189.92B | 157.32B | 134.44B | 106.92B | Stockholders Equity |
| 1.35T | 1.24T | 1.10T | 975.66B | 846.11B | 764.56B |
| Cash Flow | Free Cash Flow | ||||
| 189.90B | 126.02B | 140.68B | 70.50B | 76.09B | 120.17B | Operating Cash Flow |
| 206.82B | 154.28B | 177.87B | 102.07B | 109.04B | 131.94B | Investing Cash Flow |
| -114.34B | 5.92B | -48.29B | -96.20B | -5.26B | -29.14B | Financing Cash Flow |
| -79.37B | -126.85B | -84.12B | -36.62B | -43.89B | -88.17B |
Shionogi & Co Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| $14.80B | 11.57 | 12.99% | 2.67% | ― | ― | ||
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
| $2.21B | 15.17 | 13.50% | ― | ― | ― | ||
| $7.66B | 23.52 | 5.34% | 4.20% | ― | ― | ||
| $2.23B | 16.67 | 7.90% | 1.81% | ― | ― | ||
| $46.89B | 61.55 | 1.50% | 4.71% | ― | ― | ||
| $1.76B | 10.69 | 11.16% | 3.01% | ― | ― |
* Healthcare Sector Average
Performance Comparison
SGIOF
Shionogi & Co
15.20
2.39
18.66%
DNPUF
Sumitomo Dainippon Pharma Co
5.76
3.51
156.00%
ESALF
Eisai Co
27.50
-13.66
-33.19%
HTSUF
Hisamitsu Pharmaceutical Co
32.30
8.83
37.62%
TKPHF
Takeda Pharmaceutical Co
29.40
3.71
14.44%
TSMRF
Tsumura & Co
29.95
4.98
19.94%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.